LINC00665 and prostate cancer: As shown in Table 2, high expression of LINC00665 was significantly associated with decreased overall survival in 11 cancer patients, including breast cancer [11,13], prostate cancer [15,16], ovarian cancer [17,18,44], gastric cancer [24], hepatocellular carcinoma [3,26,27], cholangiocarcinoma [8], non-small cell lung cancer [7], lung adenocarcinoma [1,33,35], glioma [36], thymus epithelial tumor [37], and osteosarcoma [2,38].